Research
Hormonal
Semaglutide provides robust cardiovascular risk reduction (MACE) in patients with Type 2 Diabetes and established cardiovascular disease, independent of glycemic control improvements.
If you have obesity and established heart disease, semaglutide (2.4mg weekly) significantly reduces your risk of major adverse cardiovascular events (MACE), even if you do not have diabetes. This benefit is driven by weight loss and cardiometabolic improvement, not just blood sugar control.
StrongSupportsHIGH confidence
This finding is particularly relevant, as it demonstrates that cardiovascular risk reduction does not necessarily require improvements in glycaemic control, but may instead derive from weight loss and global improvement in the cardiometabolic profile.
Why this rating
Based on a large randomized clinical trial (SELECT) with significant reduction in MACE.
Source
Tirzepatide and semaglutide: different twins?
A. Cesaro et al. · European Heart Journal Supplements · 2026
DOI 10.1093/eurheartjsupp/suag028
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide (dual GIP/GLP-1 agonist) produces significantly greater weight loss and waist circumference reduction than semaglutide (selective GLP-1 agonist) in adults with obesity without diabetes.Strong
- Tirzepatide's dual GIP/GLP-1 receptor agonism provides a synergistic mechanism that enhances weight loss and mitigates gastrointestinal side effects compared to selective GLP-1 agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →